TY - JOUR
T1 - Present and future breast cancer management-bench to bedside and back
T2 - A positioning paper of academia, regulatory authorities and pharmaceutical industry
AU - Bartsch, R.
AU - Frings, S.
AU - Marty, M.
AU - Awada, A.
AU - Berghoff, A. S.
AU - Conte, P.
AU - Dickin, S.
AU - Enzmann, H.
AU - Gnant, M.
AU - Hasmann, M.
AU - Hendriks, H. R.
AU - Llombart, A.
AU - Massacesi, C.
AU - von Minckwitz, Minckwitz, G.
AU - Penault-Llorca, F.
AU - Scaltriti, M.
AU - Yarden, Yosef
AU - Zwierzina, H.
AU - Zielinski, C. C.
N1 - Roche Austria; sanofi-aventis; Novartis; Roche; Pfizer; Sanofi; GlaxoSmithKline; Merck-Serono; GSKRB has received honoraria, travel and research support from Roche Austria. SF is an employee and shareholder of Hoffmann-La Roche Ltd. MM is consultant for Celgene, Merck Sharp Dhome, Oncoethix, Roche and Sanofi Aventis. PC is member of the advisory boards of Roche, Novartis and received research grants of GSK, Novartis and Roche. SD is an employee of Eli-Lilly. MG received research grant by sanofi-aventis, Novartis, Roche, Pfizer and honoraria by Amgen, Pfizer, Novartis, GlaxoSmithKline, Bayer, Sandoz, AstraZeneca, GenomicHealth and Nanostring Technologies. MH is an employee of Hoffmann-La Roche Ltd. CM is an employee of Novartis Pharmaceuticals. GvM received research funding by Roche, Sanofi, GlaxoSmithKline, Novartis and honoraria by Roche. YY is consultant of Quintiles Innovations, Bioline Rx, Symphogen and received research grant of Merck-Serono. CCZ received honoraria by Hoffmann-La Roche, GlaxoSmithKline and Boehringer Ingelheim. All remaining authors have declared no conflicts of interest.
PY - 2014/4
Y1 - 2014/4
N2 - Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.
AB - Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.
UR - https://www.scopus.com/pages/publications/84897035109
U2 - 10.1093/annonc/mdt531
DO - 10.1093/annonc/mdt531
M3 - Article
SN - 0923-7534
VL - 25
SP - 773
EP - 780
JO - Annals of Oncology
JF - Annals of Oncology
IS - 4
ER -